Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RAB7A-interacting MON1-CCZ1 complex subunit 1 (RIMOC1) is a cytosolic and nucleoplasmic protein that plays a key role in the removal of damaged mitochondria via mitophagy. It does so by controlling the stability and localization of RAB7A, a small GTPase involved in late endosome/lysosome trafficking. RIMOC1 is required for the recruitment of RAB7A and ATG9A vesicles to mitochondria, and it promotes the stability of RAB7A by inhibiting its proteasomal degradation during mitophagy. While diseases such as Osteochondritis dissecans and Charcot-Marie-Tooth Disease are associated with this gene, there is currently no evidence that RIMOC1 serves as a direct therapeutic target, nor are there drugs targeting it specifically[1][3][5][7]. Its main classification is as a protein complex subunit involved in mitochondrial quality control.
None identified (no drugs targeting RIMOC1 directly; biological role is regulatory in mitophagy rather than direct pharmacological action)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RAB7A-interacting MON1-CCZ1 complex subunit 1 (RIMOC1).